<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">GIGANTE, MARC</style></author><author><style face="normal" font="default" size="100%">LI, GUORONG</style></author><author><style face="normal" font="default" size="100%">FERLAY, CELINE</style></author><author><style face="normal" font="default" size="100%">PEROL, DAVID</style></author><author><style face="normal" font="default" size="100%">BLANC, ELLEN</style></author><author><style face="normal" font="default" size="100%">PAUL, STEPHANE</style></author><author><style face="normal" font="default" size="100%">ZHAO, AN</style></author><author><style face="normal" font="default" size="100%">TOSTAIN, JACQUES</style></author><author><style face="normal" font="default" size="100%">ESCUDIER, BERNARD</style></author><author><style face="normal" font="default" size="100%">NEGRIER, SYLVIE</style></author><author><style face="normal" font="default" size="100%">GENIN, CHRISTIAN</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Prognostic Value of Serum CA9 in Patients with Metastatic Clear Cell Renal Cell Carcinoma under Targeted Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">5447-5451</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><issue><style face="normal" font="default" size="100%">12</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: Carbonic anhydrase 9 (CA9) has been found to be one of most powerful biomarkers for clear-cell renal cell carcinoma (RCC). The serum CA9 is detectable. The aim of this study was to evaluate the potential prognostic role of serum CA9 in patients with metastatic clear-cell RCC patients under targeted therapy. Patients and Methods: Serum samples came from the randomized phase 2 TORAVA trial. All patients received a targeted therapy (arm A designed as experimental group: temsirolimus and bevacizumab combination; arm B: sunitinib; arm C: interferon-alfa and bevacizumab). Seventy cases of metastatic clear-cell RCC were analyzed. There were 49 males and 21 females. The age ranged from 33.5 to 79.1 years with a median of 61.2 years. Serum samples were collected before treatment. Serum CA9 was quantified by enzyme-linked immunosorbent assay (ELISA). The correlation of the serum CA9 levels with the clinical parameters, treatment response and overall survival was analyzed. Overall survival estimates were calculated using the Kaplan-Meier method and compared by the log-rank test. Results: Serum concentrations of CA9 ranged between 0 and 897.3 pg/ml, with an average of 94.4±176.6 pg/ml. There was no association between serum CA9 and clinical parameters such as Eastern Cooperative Oncology Group (ECOG) Performance Status (p=0.367) or Motzer classification (p=0.431). The serum CA9 levels were lower in the response group (64.7±104.7 pg/ml) than the no-response group (108.2±203.8 pg/ml), but the difference was not statisticlly significant (p=0.366). For the patient group overall, the Kaplan-Meier survival curve showed that high serum CA9 levels were significantly associated with shorter overall survival (hazard ratio=2.65, 95% confidence interval=1.19-5.92, log-rank test p=0.0136). For the major group of patients treated with temsirolimus and bevacizumab, the Kaplan-Meier survival curve showed that high serum CA9 levels were significantly associated with shorter overall survival (p=0.0006). Conclusion: Serum CA9 levels may be of clinical interest to predict the outcome for patients under targeted therapy for metastatic clear-cell RCC. CA9 may be used to select patients with metastatic clear cell RCC for clinical trials.</style></abstract></record></records></xml>